Sector News

B-MS to build near-$1 billion biologics facility in Ireland

November 14, 2014
Life sciences
Bristol-Myers Squibb has unveiled plans to construct a new biologics manufacturing facility in Ireland which will create up to 400 new jobs as part of a near $1 billion investment.
 
The 30,000-square metre project will house six bioreactors and a purification area as well as office and laboratory space. It will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant in Cruiserath, Co Dublin.
 
B-MS said the full cost is anticipated to be “comparable to the approximately $900 million investment to construct and operationalise the company’s biologics manufacturing facility in Devens, Massachusetts”. Some 350-400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the plant which is estimated to be operational in 2019.
 
Taoiseach Enda Kenny said the news “is a huge boost to the Irish economy”, noting that 1,000 construction jobs will also be created in the initial phase. He added that the government “has a plan to secure recovery so that Ireland can attract new jobs and investments”.
 
B-MS chief executive Lamberto Andreotti said the investment “reflects the strength of our business and the increasingly important role that biologic medicines will play” in the firm’s future. He noted that “for 50 years, B-MS has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy”.
 
By Kevin Grogan
 
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach